Back to top

Bank of America Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG, with a price target o...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

CRISPR Therapeutics AG (CRSP)